Cambridge Healthtech Institute’s 7th Annual

Gene Therapy Manufacturing

Ensuring the Cost-Effective Supply of Viral Vectors

August 17- 18, 2022


Cambridge Healthtech Institute’s Gene Therapy Manufacturing meeting tackles the practical challenges facing the production, scale-up and manufacture of viral and non-vector-based gene therapies. Topics include AAV, lentivirus and retrovirus process development, vector development, scale-up and purification for clinical and commercial supply.


Coverage will include, but is not limited to:


  • Strategies to optimize production – packaging, cell line development, ensuring consistency
  • Upstream production and scaling-up – moving to suspension
  • Production platforms
  • Process intensification
  • Commercial manufacturing strategies – external vs. internal vs. shared capacity
  • Downstream processing for full/empty capsids
  • Non-viral gene therapy technical development and manufacture
  • Formulation – buffer choice, frozen vs. non-frozen
  • Drug product and administrating to patients


The deadline for priority consideration is February 4, 2022.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


Opportunities for Participation:



For more details on the conference, please contact:

Daniel Barry

Senior Conference Director

Cambridge Healthtech Institute

Phone: +44 7837 651 303



For sponsorship information, please contact:


Companies A-K

Sherry Johnson

Sr. Business Development Manager

Cambridge Healthtech Institute

Phone: +1 781-972-1359



Companies L-Z

Jon Stroup

Sr. Business Development Manager

Cambridge Healthtech Institute

Phone: +1 781-972-5483


Submit a Speaker Proposal